Is Time to Change to Halogenated Drugs in Cardiac Surgery, What do we have to do with Propofol?

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|20|34|5497-5505

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.34, 2014-10, pp. : 5497-5505

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antimicrobial resistance - why do we have it and what can we do about it?

By Dougherty T.J.   Pucci M.J.   Bronson J.J.   Davison D.B.   Barrett J.F.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 8, 2000-08 ,pp. : 1707-1709

Informa Healthcare

Access to resources Recommend Favorite

What We Do Not Know About Organizations of People Who Use Drugs

By Friedman Samuel R.   Schneider Eric   Latkin Carl  

Substance Use & Misuse, Vol. 47, Iss. 5, 2012-03 ,pp. : 568-572

Informa Healthcare

Access to resources Recommend Favorite

Treatment of central sensitization in patients with ‘‘unexplained’’ chronic pain: what options do we have?

By Nijs Jo   Meeus Mira   Van Oosterwijck Jessica   Roussel Nathalie   De Kooning Margot   Ickmans Kelly   Matic Milica  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 7, 2011-05 ,pp. : 1087-1098

Informa Healthcare

Access to resources Recommend Favorite

Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here?

By Urban Thomas J   Goldstein David B   Watkins Paul B  

Pharmacogenomics, Vol. 13, Iss. 7, 2012-05 ,pp. : 735-738

Future Medicine

Access to resources Recommend Favorite

MRSA – what is it, and how do we deal with the problem?

By Barrett John F  

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 2, 2005-04 ,pp. : 253-265

Informa Healthcare

Access to resources Recommend Favorite